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The prevalence of depressive disorders is growing worldwide, notably due to stagnation
in the development of drugs with greater antidepressant efficacy, the continuous large
proportion of patients who do not respond to conventional antidepressants, and the
increasing rate of chronic medical conditions associated with an increased vulnerability
to depressive comorbidities. Accordingly, better knowledge on the pathophysiology of
depression and mechanisms underlying depressive comorbidities in chronic medical
conditions appears urgently needed, in order to help in the development of targeted
therapeutic strategies. In this review, we present evidence pointing to inflammatory
processes as key players in the pathophysiology and treatment of depressive
symptoms. In particular, we report preclinical and clinical findings showing that
inflammation-driven alterations in specific metabolic pathways, namely kynurenine and
tetrahydrobiopterin (BH4) pathways, leads to substantial alterations in the metabolism
of serotonin, glutamate and dopamine that are likely to contribute to the development
of key depressive symptom dimensions. Accordingly, anti-inflammatory interventions
targeting kynurenine and BH4 pathways may be effective as novel treatment or as
adjuvants of conventional medications rather directed to monoamines, notably when
depressive symptomatology and inflammation are comorbid in treated patients. This
notion is discussed in the light of recent findings illustrating the tight interactions between
known antidepressant drugs and inflammatory processes, as well as their therapeutic
implications. Altogether, this review provides valuable findings for moving toward
more adapted and personalized therapeutic strategies to treat inflammation-related
depressive symptoms.
Keywords: inflammation, neuroinflammation, kynurenines, tetrahydrobiopterin (BH4), monoamines, depressive
symptoms, antidepressant treatment, anti-inflammatory strategies
INTRODUCTION
Depression currently represents a global public health concern. Not only its prevalence is steadily
increasing worldwide but also it relates to a stronger risk of morbidity and death (World Health
Organization, 2017). In addition, despite advances made in the treatment of depression, at least one
third of depressed patients fail to respond to conventional medications (Rush et al., 2006). Further
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contributing to the global burden of depression, most of the
chronic diseases whose prevalence is also continuously rising,
including metabolic, autoimmune and cardiovascular diseases,
are associated with an increased risk of depression (Luppino et al.,
2010; Capuron et al., 2017; Zuzarte et al., 2018). The latter impairs
the quality of life of affected patients and emerges as a potent
contributor of subsequent medical complications (Penninx et al.,
2013). Thus, a better knowledge of the pathophysiological bases
of depression and identification of new targets relevant for
therapeutic advances are still clearly needed.
While different neurobiological systems are likely involved in
the pathophysiology of depression, this review will summarize
evidence that supports a main role for inflammatory processes.
First dedicated to decipher the intricate relationship between
the innate immune system and the brain, initial research
performed in the field of psychoneuroimmunology started to
identify the molecular mechanisms underlying the behavioral
and neuropsychiatric consequences of inflammation (for review
Dantzer et al., 2008; Capuron and Miller, 2011). Meanwhile,
converging clinical studies reported a link between increased
circulating levels of inflammatory factors and greater risk of
developing mood alterations (Capuron et al., 2002; Evans et al.,
2005). Altogether, these findings have fostered still on-going
investigations aiming to further identify the neurobiological
pathways targeted by cytokines and in turn mediating their
neuropsychiatric effects. Moreover, in line with recent data
suggesting that elevated basal inflammation, as reported in
obesity and metabolic syndrome, may contribute to impair the
therapeutic efficiency of conventional antidepressant treatment
(Kloiber et al., 2007; Toups et al., 2013), a corollary question arises
as to whether inflammatory factors, their signaling pathways
and/or neurobiological targets, may represent potential targets
for new pharmacological interventions. This review will discuss
those issues in the light of recent findings providing a deeper
mechanistic understanding of the role of inflammation in the
pathophysiology of depression and relevant insights for novel
therapies.
THE INFLAMMATORY HYPOTHESIS OF
DEPRESSION
Although progressively extended to several mental illnesses,
including bipolar disorders, anxiety disorders or schizophrenia
(Potvin et al., 2008; Hoge et al., 2009; Barbosa et al., 2013),
the notion that inflammation may be involved in the
pathophysiology of neuropsychiatric symptoms was particularly
studied in the context of depression (Raison et al., 2006;
Capuron and Miller, 2011). The first studies strongly supporting
this notion report higher circulating levels of inflammatory
mediators, including C-reactive protein (CRP), cytokines
(particularly interleukin-6, IL-6) and different chemokines, in
depressed individuals compared to healthy controls (Dowlati
et al., 2010; Leighton et al., 2018). Moreover, longitudinal
investigations reveal that higher inflammatory profiles predict
the development of depressive symptoms (Valkanova et al., 2013;
Smith et al., 2018). To move from correlation to causality, chronic
cytokine administration has been shown to induce depression
in up to 50% of medically ill patients undergoing cytokine
immunotherapy (Musselman et al., 2001; Capuron et al., 2002;
Kawase et al., 2016). Similarly, direct administration of cytokines,
or cytokine inducers, such as lipopolysaccharide (LPS), to
healthy volunteers triggers depressive symptoms (Schedlowski
et al., 2014; Engler et al., 2017). Consistent with clinical findings,
both acute or chronic immune challenges in rodents induce
sustained depressive-like and anxiety-like behaviors (Merali
et al., 2003; Frenois et al., 2007; Moreau et al., 2008; Klaus et al.,
2016). Conversely, anti-inflammatory compounds reduce these
behaviors in animal models of inflammatory diseases (Llorens-
Martin et al., 2014; Zaminelli et al., 2014; Norden et al., 2015).
Likewise, directly targeting specific inflammatory cytokines
decreases mood alterations in both humans and rodents (Tyring
et al., 2006; Kekow et al., 2010; Haji et al., 2012; Bayramgürler
et al., 2013; Fleming et al., 2015).
Inflammation-induced behavioral changes have been
shown to rely on a large communication network allowing
inflammatory cytokines [e.g., IL-1β, IL-6, tumor necrosis factor
(TNF)-α], which are released peripherally by activated immune
cells, to reach the brain through humoral, nervous and chemical
pathways and to locally induce production of brain cytokines
by activated microglia, the immune cells of the brain. These
cytokines in turn influence pathways involved in the regulation
of behavior and mood, including neurotransmitter metabolism,
neuroendocrine function and neural plasticity (Castanon
et al., 2004; Frenois et al., 2007; Dantzer et al., 2008; Capuron
and Miller, 2011). These neuroimmune interactions not only
coordinate the immune response, but also the development
of adaptive behavioral changes collectively referred to as
sickness behavior. These changes, which include weakness,
listlessness, malaise, anorexia and fatigue, have been shown
to be necessary for recovery, by helping the body to actively
fight against aggressions. Inflammatory activation is usually
transient and controlled by anti-inflammatory mechanisms to
warrant time-limitation and reversibility of sickness behavior.
Conversely, failure of those control mechanisms that allows
development of sustained inflammation has been shown to
represent a major leading cause of inflammation-related mood
alterations (Dantzer et al., 2008; Capuron and Miller, 2011;
Castanon et al., 2014; Capuron and Castanon, 2017). Indeed, if
inflammation initially serves a protective function in controlling
infection and promoting tissue repair, it can in the long run
interfere with brain neurotransmission and cause tissue damages,
what ultimately contributes to promote sustained behavioral
and mood alterations. Interestingly, compelling clinical studies
revealed that patients under cytokine immunotherapy display
symptoms spanning multiple dimensions from neurovegetative
(e.g., fatigue, decreased tone and motivation) to neuropsychiatric
(e.g., depressed mood, anxiety, cognitive alterations) levels
(Musselman et al., 2001; Capuron and Miller, 2011; Capuron
and Castanon, 2017). Importantly, these symptoms differ
in their time-course and responsiveness to prophylactic
treatment with classical antidepressant drugs, particularly
those targeting serotonin neurotransmission. In particular,
neurovegetative symptoms appear early after initiation of
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cytokine immunotherapy and in a large proportion of patients.
On the contrary, neuropsychiatric symptoms progressively
develop after several weeks of cytokine administration and only
affect 30–50% of patients. These last symptoms can be prevented
by antidepressant treatment, in contrast to neurovegetative
symptoms that are not, or only minimally, responsive to this
intervention (Musselman et al., 2001; Capuron and Miller, 2011).
Altogether, these findings suggested the involvement of distinct
underlying mechanisms.
Strong support for this assumption came from studies
performed in immune-challenged animals in which it is possible
to experimentally dissociate sickness behavior, occurring early
after the immune stimulation, from protracted depressive-like
behaviors (Merali et al., 2003; Frenois et al., 2007; Moreau
et al., 2008; Klaus et al., 2016). First attempts to assess
the respective underlying neurobiological mechanisms have
concentrated on the same preclinical models. In that context,
it is worth mentioning that some of the behavioral changes
characterizing sickness behavior, particularly motor slowing,
could interfere with the measure of depressive-like behaviors
when assessed in paradigms based on motor responses. This
potential methodological bias has, however, been circumvented
by using several reliable and complementary behavioral tests
modeling different core symptoms of depression, and by testing
mice in these tests only once they have totally recovered from
sickness behavior (Frenois et al., 2007; Godbout et al., 2008;
O’Connor et al., 2009c). Interestingly, this experimental design
in LPS-challenged mice enabled to show a neuroanatomical
dissociation between the brain structures that underlie LPS-
induced sickness and depressive-like behaviors, respectively
(Frenois et al., 2007). It could still be argued that some
inconsistencies exist across the literature (see Biesmans et al.,
2013) and that a model of acute immune activation with LPS is
not necessarily relevant to the clinical situation. Several studies
performed in models of chronic inflammation, which can be
claimed as more suitable, however, confirmed the presence
of sustained depressive-like behaviors while sickness behavior
was not anymore detectable nor levels of circulating cytokines
elevated (Moreau et al., 2008; O’Connor et al., 2009a,b). Together
with clinical studies, all these models turned out to be very useful





Mounting clinical and preclinical findings led us and others
to propose that the multidimensional inflammation-related
symptoms may rely on the ability of inflammatory cytokines
to alter important metabolic pathways, namely kynurenine and
tetrahydrobiopterin (BH4) pathways, which in turn can impair
neurotransmission of monoamines, particularly serotonin,
glutamate and dopamine, involved in mood regulation (Dantzer
et al., 2008; Capuron and Miller, 2011; Capuron and Castanon,
2017; Haroon et al., 2017).
The Kynurenine Pathway: At the
Crossroad Between Inflammation and
Mood
The metabolism of the essential amino acid tryptophan produces
an array of crucial factors able of regulating key physiological
processes linked to behavior and mood, particularly serotonin.
Tryptophan metabolism along the kynurenine pathway (KP)
accounts for most of the tryptophan that is not used for protein
synthesis, and ultimately leads to the production of several
neuroactive metabolites, including 3-hydroxykynurenine (3-HK)
and quinolinic acid (QA), which are able to stimulate N-methyl-
D-aspartate (NMDA) glutamatergic receptors and promote
oxidative stress, and kynurenic acid (KA) that rather displays
neuroprotective properties (Figure 1) (Schwarcz and Stone,
2017). Since microglia preferentially produce QA, while KA is
synthesized by astrocytes, neurotoxicity prevails in conditions
of immune activation. Accordingly, increased plasma and/or
cerebrospinal fluid QA levels have been reported in a plethora of
conditions that encompass inflammatory and neurodegenerative
damages, together with an increased prevalence of mood
symptoms (Capuron et al., 2011; Bay-Richter et al., 2015;
Lovelace et al., 2017; O’Farrell and Harkin, 2017; Schwarcz and
Stone, 2017). More importantly, KP activation correlates with
both stretch of brain damages and severity of neuropsychiatric
symptoms (Capuron et al., 2002; Raison et al., 2010; Savitz et al.,
2015a,b). These findings prompted a surge of interest for the
involvement of KP enzymes and metabolites in inducing these
symptoms, starting by the enzyme indoleamine 2,3-dioxygenase
(IDO) that catalyzes the first and rate-limiting step of tryptophan
metabolism along the KP (Lestage et al., 2002; Moreau et al.,
2005; André et al., 2008). For example, it was shown in mice
that inoculation with Bacillus Calmette-Guerin (BCG) chronically
increases both peripheral and brain IDO activity, this activation
paralleling development of sustained depressive-like behaviors
(Moreau et al., 2008; O’Connor et al., 2009a,b). Aged mice
(Godbout et al., 2008; Wynne et al., 2010), or mice exhibiting
constitutive microglial over-activation (Corona et al., 2013)
also display sustained cytokine production after an immune
challenge, together with protracted brain IDO expression and
depressive-like behavior (Godbout et al., 2008; Wynne et al., 2010;
Corona et al., 2013). Similarly, a link between inflammation-
related brain IDO activation and depressive-like behavior has
been reported in other chronic inflammatory conditions, such as
murine models of obesity (André et al., 2014; Dinel et al., 2014).
Importantly, direct KP activation within the brain is sufficient
to alter emotional behaviors in rodents, particularly when it
occurs in key brain areas for behavior and mood, particularly
the hippocampus (Henry et al., 2009; Fu et al., 2010; Park et al.,
2011; Dobos et al., 2012; Lawson et al., 2013). By using mice with
either genetic or systemic inhibition of IDO and submitted to an
immune challenge, we and others described the causal role of
IDO activation in the induction of depressive-like and anxiety-
like behaviors (Godbout et al., 2008; O’Connor et al., 2009a,b,c;
Salazar et al., 2012; Corona et al., 2013; Gibney et al., 2013; Xie
et al., 2014; Castanon, 2015). This induction can be related to
the potential for IDO to negatively impact serotonin synthesis by
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FIGURE 1 | Kynurenine pathway activation in inflammatory conditions. The enzymatic activity of the indoleamine 2,3-dioxygenase (IDO) is increased by inflammatory
cytokines in activated monocytes, macrophages and brain microglia in inflammatory conditions. The essential amino acid tryptophan is therefore used for the
synthesis of kynurenine, and this at the expense of the synthesis of the monoamine serotonin that directly depends on the availability of its precursor and limiting
factor tryptophan. IDO activation might therefore impair serotonin neurotransmission. Kynurenine is then used to produce different neuroactive glutamatergic
metabolites, including kynurenic acid, which is neuroprotective by acting on both glutamatergic NMDA and α7-nicotinic acetylcholine (α7-nAChR) receptors, and
3-hydroxykynurenine and quinolinic acid that are rather neurotoxic by promoting oxidative stress and/or activating NMDA receptors. As the activity of the kynurenine
monooxygenase (KMO) that synthesizes 3-hydroxykynurenine is increased in activated microglia by inflammatory cytokines, increased production of kynurenine is
ultimately associated with skewing of the kynurenine metabolic balance toward increased neurotoxicity. By impairing serotonin neurotransmission and promoting
neuronal damages, cytokine-induced kynurenine pathway activation can therefore contribute to the development of inflammation-driven depressive symptoms.
TrypOH, tryptophan hydroxylase; KAT, kynurenine aminotransferase; KYNU, kynureninase; 3-HAO, 3-hydroxyanthranilic acid oxygenase.
decreasing bioavailability of tryptophan. However, the fact that
immune activation is actually associated with increased serotonin
turnover (Godbout et al., 2008; O’Connor et al., 2009c; Gibney
et al., 2013; Parrott et al., 2016a), regardless of concomitant IDO
activation (O’Connor et al., 2009c), weakens this hypothesis.
These findings may rather suggest intervention of other cytokine-
induced alterations in serotonin neurotransmission, including
modulation of serotonin transporter and receptors (Zhu et al.,
2006). Follow-up work is therefore needed to deeply study the
consequences of KP activation on the temporal and spatial
patterns of serotonin-related processes.
An alternative explanation for the involvement of KP
activation in inflammation-related mood symptoms is the
generation of neurotoxic glutamatergic kynurenine metabolites,
as they have been clinically related to the severity of mood
alterations (Capuron et al., 2011; Bay-Richter et al., 2015; Haroon
et al., 2017; Schwarcz and Stone, 2017). In line with the well-
established role of altered neuron integrity and/or function
in subtending the clinical outcomes of neurodegenerative
diseases, neuronal damages have been also linked to the
development of inflammation-induced depressive symptoms
(Dantzer and Walker, 2014). This may particularly involve the
NMDA receptors, which have recently drawn much attention
in the field of depression research (Dantzer and Walker, 2014;
Haroon et al., 2017). Supporting further this notion, preclinical
studies report that depressive-like behaviors induced by LPS
challenge (Parrott et al., 2016a,b) or related to neuropathic
pain (Laumet et al., 2017) are associated with skewing of the
kynurenine metabolic balance toward production of neurotoxic
metabolites, and this in a region-specific manner with the
hippocampus being particularly affected. Moreover, systemic
administration of kynurenine (O’Connor et al., 2009c; Salazar
et al., 2012; Agudelo et al., 2014) or 3-HK (Parrott et al.,
2016a,b) dose-dependently impairs emotional behaviors, whereas
mice deficient for IDO are protected against NMDA receptor-
mediated excitotoxicity (Mazarei et al., 2013). Of note, NMDA
receptor blockade abrogates inflammation-induced depressive-
like behavior (Walker et al., 2013), along with selective inhibition
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of downstream KP enzymes, i.e., kynurenine 3-monooxygenase
(KMO) or 3-hydroxyanthranilic acid dioxygenase (HAAO) that
ultimately synthesize the NMDA receptor agonist QA (Parrott
et al., 2016b; Laumet et al., 2017). Interestingly, this especially
improves depressive-like behaviors related to clinical behavioral
despair (i.e., immobility in the tail suspension test), while
being less efficient on behavioral changes rather modeling
anhedonia (i.e., sucrose preference) (Parrott et al., 2016b).
These results are particularly relevant to help identifying the
neurobiological mechanisms that, respectively, underlie the
different inflammation-related depressive symptoms. As each
behavior/symptom is functionally subtended by preferential
activation of selective neuronal pathways in discrete brain
regions, such dimensional dissociation may rely on the regional
differences of KP activation reported in those experimental
studies (Parrott et al., 2016a,b; Laumet et al., 2017). While
LPS-induced brain expression of cytokines is largely region-
independent, the 3-HK/KA ratio is significantly increased
in the hippocampus, but not central amygdala or nucleus
accumbens (Parrott et al., 2016a). Consistent with these
preclinical findings, post-mortem studies of depressed patients
link severe depression with increased microglial QA detection
in selective cortical subregions (Steiner et al., 2011). Conversely,
a higher neuroprotective index, as reflected by elevated KA/QA
ratio, positively correlates with hippocampal volume in clinically
depressed but non-medicated patients (Savitz et al., 2015a).
Otherwise, the above-mentioned dissociation between KP
activation and development of specific depressive symptoms may
rather reflect involvement of other metabolic pathways and/or
neurotransmission systems (Capuron and Castanon, 2017). This
assumption is nicely supported by a recent study showing
that inflammation-induced impairment of motivation-driven
behaviors is independent from IDO activation since it persists
in LPS-treated IDO deficient mice (Vichaya et al., 2018). With
regard to inflammation-related motivational deficits, the BH4
pathway that can ultimately impair dopamine neurotransmission
appears as a likely candidate (Felger and Treadway, 2017). This
is supported by data obtained in mice deficient in BH4, which
exhibit dopamine-related behavioral alterations (Choi and Tarazi,
2010). Both alternatives are not necessarily disconnected since
KA has been shown to modulate striatal dopaminergic tone, by
acting on α7-nicotinic acetylcholine receptors (Wu et al., 2007),
while pharmacological activation of these receptors mitigates
anhedonia in a mouse model of chronic stress (Zhao et al.,
2017). Moreover, clinical data report an inverse association
between circulating KA/QA ratio and the degree of anhedonia in
depressed patients (Savitz et al., 2015a).
The BH4 Pathway: A Key Player in
Neurobiological Modulation of
Depressive Symptoms
BH4 is a pivotal cofactor for the optimal functioning of the
nitric oxide synthase isoforms (NOS) and three aromatic amino
acid hydroxylases: phenylalanine hydroxylase (PAH), tryptophan
hydroxylase (trypOH) and tyrosine hydroxylase (TH) (Thöny
et al., 2000; Sumi-Ichinose et al., 2001). Accordingly, it is required
for the synthesis of dopamine, serotonin and nitric oxide from
the essential amino acids tyrosine, tryptophan and arginine,
respectively (Sumi-Ichinose et al., 2001). BH4 de novo synthesis
involves the sequential activation of three enzymes, the first
one, GTP-cyclohydrolase 1 (GCH1) being the rate-limiting step
(Thöny et al., 2000) (Figure 2). The activity of this enzyme,
which is co-localized with the monoamine-containing cells, has
been shown to differ according to the brain area (Sawada et al.,
1986; Nagatsu et al., 1995; Dassesse et al., 1997). Inflammatory
cytokines, including IL-1β, interferon-γ and TNF-α, are able to
induce both GCH1 expression and activity, therefore increasing
BH4 synthesis (Shi et al., 2004). At the post-translational level,
GCH1 is inhibited by BH4 and stimulated by phenylalanine,
through its complex formation with the cyclohydrolase feedback
regulatory protein (GFRP) (Neurauter et al., 2008). This process
ensures tightly keeping BH4 levels within a physiological range
in the body. BH4 is also oxidized to BH2, which can, however,
be conversely converted back to BH4 by the dihydrofolate
reductase (DHFR) (Harada et al., 1993). In fine, the net cellular
bioavailability of BH4 likely results therefore from the balance
between its de novo synthesis, its oxidation to BH2, and its
regeneration by DHFR.
Several clinical conditions have been associated with a defect
in the BH4-pathway, mainly linked to alterations affecting
the different enzymatic steps. Mutation of GCH1 results in
greatly reduced BH4 level, which has been shown to cause
neurological diseases, such as dopamine-responsive dystonia
(Ichinose et al., 1994; Müller et al., 2002). Mice genetically
deficient for BH4 (hph1 model) display decreased dopamine
levels and increased depressive-like behaviors (Nasser et al.,
2014). Supporting preclinical findings, patients with GCH1
deficiency have been shown to exhibit an increased frequency
of psychiatric disorders, including depression and anxiety (Van
Hove et al., 2006; Trender-Gerhard et al., 2009). Moreover,
we have recently reported that variations in markers of
GCH1 activity correlate with neurovegetative symptoms and
inflammatory factors in elderly persons (Capuron et al., 2011).
Low BH4 levels have also been found in postmortem brains of
subjects with a history of severe depression (Blair et al., 1984).
Conversely, raised urine and plasma total biopterin levels are
measured in depressed patients (Duch et al., 1984; Garbutt et al.,
1985; Knapp and Irwin, 1989; Hashimoto et al., 1994; Abou-
Saleh et al., 1995), suggesting impaired BH4 metabolism. In
addition, reduced GCH1 activity, assessed through the increased
phenylalanine/tyrosine ratio, has been reported in depressive
patients responding to electroconvulsive therapy (Anderson
et al., 1994). This phenylalanine/tyrosine ratio is also used
as indicator of BH4 availability and PAH activity and may
serve therefore as an indirect biomarker of dopamine and
norepinephrine synthesis (Neurauter et al., 2008; Capuron et al.,
2011).
In Human, low PTPS activity directs the production of
neopterin at the expense of BH4 in conditions of GCH1
stimulation, such as inflammation. Neopterin is therefore
considered as a marker of cell-mediated immunity in
inflammatory conditions (Murr et al., 2002). Increased
phenylalanine levels and phenylalanine/tyrosine ratio is reported
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FIGURE 2 | Inflammation-associated BH4 pathway. Cytokine production elicited in response to an immune challenge induces GTP-cyclohydrolase-1 (GCH1),
6-pyruvoyl-tetrahydropterin synthase (PTPS) and sepiapterin reductase (SR) activation (de novo synthesis pathway), leading to tetrahydrobiopterin (BH4) synthesis.
GCH1 activity is modulated by the interaction of GTP-cyclohydrolase feedback protein (GFRP) and effectors molecules, BH4 and phenylalanine. BH4 is rapidly
oxidized to BH2, which is subsequently reduced back to BH4 by the enzyme DHFR, representing a salvage pathway. In Human, PTPS becomes rate-limiting under
inflammatory challenge and drives neopterin formation to the detriment of BH4. Under inflammatory conditions, BH4 is preferentially used as cofactor for NOS (nitric
oxide synthase) activity, for synthesis of nitric oxide (NO), leading to a lower availability for PAH (phenylalanine hydroxylase), TH (tyrosine hydroxylase) and TrypOH
(tryptophan hydroxylase) activities and reduced synthesis of monoamines. NH2TP: 7,8Dihydroneopterin triphosphate; 6PTP: 6Pyruvoyl-tetrahydrobiopterin.
in patients suffering from chronic inflammatory conditions,
this increase being correlated with neopterin concentrations
(Neurauter et al., 2008; Ploder et al., 2008; Zangerle et al., 2010;
Murr et al., 2014; Hirayama et al., 2016; Ormstad et al., 2016). It is
well known that inflammatory stimulation activates the inducible
NOS, which considerably increases the use of BH4 for optimal
enzymatic activity, and induces formation of large amounts
of oxygen radicals that in turn contribute to the oxidative loss
of BH4 (Werner et al., 2003). Both increased use and loss of
BH4 driven by a chronic inflammatory state may synergistically
act to alter the function of BH4-dependent enzymes and then
compromise the biosynthesis of monoamines, which may
contribute to development of mood disorders (Neurauter et al.,
2008; Felger et al., 2013a,b).
Preclinical studies show changes in brain dopamine and
serotonin, and/or respective metabolite levels after an immune
stimulation (Kamata et al., 2000; Kumai et al., 2000; Kitagami
et al., 2003; Sato et al., 2006). Interestingly, inflammation-
induced impairment of dopamine neurotransmission, which may
involve induction of oxidative damages, has been proposed as a
potential mechanism underlying motivational changes reported
in LPS-challenged mice (Vichaya et al., 2018). Clinical studies
also reveal some functional alterations of the dopaminergic
reward system, in association with impairment in motivation
and motor slowing (Capuron et al., 2007; Eisenberger et al.,
2010; Capuron et al., 2012). Similar blunting of neural responses
to reward has been observed in condition of dietary depletion
of amino acid precursors for dopamine synthesis (Bjork et al.,
2014). Decreased dopamine synthesis and release have been
confirmed using microdialysis in monkeys and mice under
inflammatory conditions (Felger and Treadway, 2017 for review).
Some evidence also shows that inflammatory cytokines may
alter the presynaptic dopamine storage through changes in
expression and function of the vesicular monoamine transporter
(VMAT2) (Kazumori et al., 2004). Moreover, functional changes
of the dopamine reuptake pump, DAT, have been suggested in
neuroinflammatory conditions associated to HIV infection or
prenatal LPS challenge (Gelman et al., 2006; Tien et al., 2013).
Then, a reduced presynaptic vesicular storage and/or altered
DAT-reuptake of dopamine could together lead to reduced
dopamine turnover in inflammatory conditions.
Based on these data, the BH4 pathway is emerging as an
important regulator for a number of symptoms and pathologies
associated with over-production of inflammatory mediators.
Moreover, as previously mentioned recent data suggest a link
between KP and BH4 pathways that could act synergistically
upon inflammatory conditions to compromise monoamine
synthesis. Thus, increased xanthurenic acid, a metabolite of
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3-HK, has been shown to directly lower BH4 biosynthesis by
inhibiting sepiapterin reductase (Haruki et al., 2016). Similarly,
it has been suggested that a concurrent upregulation of
kynurenines and BH2 production may lead to a combined
up-regulated activity of NOS (by kynurenines) and decreased
availability of BH4, as NOS cofactor (Oxenkrug, 2011). Such a
combination results in an uncoupling of NOS and consequently
reduced production of NO in favor of “inflammogenic” reactive
oxygen species (ROS), which cause further oxidative BH4
loss. Altogether, these data strongly support the role of both
kynurenine and BH4 pathways in development of inflammatory-
related depressive symptoms.
THERAPEUTIC IMPLICATIONS
One of the major issues when dealing with depressive disorders
is the heightened resistance to standard antidepressant therapy
(Rush et al., 2006). In that context, the possibility of alternatively
and/or concomitantly targeting inflammatory processes to
improve clinical outcomes has recently received particular
attention (Schmidt et al., 2016; Colpo et al., 2018; Kappelmann
et al., 2018; Shariq et al., 2018; Zuzarte et al., 2018). It has been
postulated that most classical antidepressants known to primary
act on monoamine neurotransmission [i.e., selective serotonin
reuptake blockers: SSRIs, tricyclic antidepressants (TCA) acting
on norepinephrine reuptake, and antidepressants acting on both
serotonin and norepinephrine reuptake: SNRI] may also act on
inflammation since they display anti-inflammatory properties
both peripherally and within the brain (Lanquillon et al., 2000;
Tynan et al., 2012; Strawbridge et al., 2015; Wiêdłocha et al.,
2018). Importantly, they not only reduce circulating cytokine
levels, but also downstream activation of the KP (Ara and Bano,
2012; Zoga et al., 2014; Reus et al., 2015), ultimately correcting the
imbalance between neuroprotective and neurotoxic kynurenine
metabolites (Kocki et al., 2012; Eskelund et al., 2017). Hence,
sustained SSRI treatment in rodent models of depression reduces
QA levels in different brain regions known to be involved in
mood regulation (Eskelund et al., 2017). Moreover, variations
in the genes coding for IDO and GCH1 have been shown to
predict SSRI treatment outcome in depressive patients (Cutler
et al., 2012; Kishi et al., 2012), further supporting a role for
both pathways in the therapeutic response. Of note, the immune-
modulatory impact of antidepressants differs depending on their
class, with SSRI and SNRI drugs being mostly anti-inflammatory,
while TCAs rather displaying in some studies pro-inflammatory
properties (Hamer et al., 2011; Vogelzangs et al., 2012; Nazimek
et al., 2016; Chen et al., 2018). Further highlighting the
complexity of the relationship between antidepressants and
inflammation, a given antidepressant drug can display both pro-
or anti-inflammatory properties depending on what immune
parameter is assessed (e.g., cytokine release or activation of
specific intracellular signaling pathways) (Horowitz et al., 2014).
Mounting evidence suggests that treatment resistance might
be predicted by elevated inflammation, whether linked to
specific gene variants (Baune et al., 2010), activation of selective
intracellular pathways (Horowitz et al., 2014) or the presence
of chronic inflammatory conditions/diseases (Luppino et al.,
2010; Vogelzangs et al., 2012; Hughes and Kumari, 2017). In
support of this notion, conditions such as overweight or obesity,
which are characterized by a chronic low-grade inflammatory
state together with a higher prevalence of depression, have been
recently shown to relate to a greater risk of non-response to
conventional antidepressants (Kloiber et al., 2007; Toups et al.,
2013; Woo et al., 2016; Jantaratnotai et al., 2017). Interestingly, in
those conditions, systemic inflammation is associated with both
KP activation, as revealed by increased circulating kynurenine
levels and expression of the KP enzymes – notably neurotoxic
metabolites – in the adipose tissue of obese subjects (Favennec
et al., 2015; Alemán et al., 2017), and mood symptoms (Capuron
et al., 2008; Daly, 2013). Similar results were obtained in
preclinical models of obesity (Dinel et al., 2011, 2014; André
et al., 2014; Boitard et al., 2014; Castanon et al., 2015; Almeida-
Suhett et al., 2017; de Cossio et al., 2017). Interestingly, weight
loss that reduces inflammation and KP activation (Cancello and
Clement, 2006; Alemán et al., 2017) correlates with significant
mood improvement (mery et al., 2007; Capuron et al., 2011).
Beside KP activation, studies reporting increased neopterin levels
in obese (Brandacher et al., 2006; Oxenkrug et al., 2011; Mangge
et al., 2014) also suggest the potential involvement of BH4
pathway in obesity-related depressive comorbidity, consistent
with impairment of dopamine neurotransmission reported in
obesity (Sharma and Fulton, 2013; Krishna et al., 2015).
Compelling evidence supports the notion that anti-
inflammatory interventions may be effective as novel
antidepressants or adjuvants of conventional antidepressants, as
long as inflammation and depressive symptoms are comorbid in
treated patients (Strawbridge et al., 2015; Kappelmann et al., 2018;
Köhler et al., 2016; Schmidt et al., 2016; Jantaratnotai et al., 2017;
Jha and Trivedi, 2018) (Table 1). For example, non-steroidal
anti-inflammatory drugs (NSAIDs) improve antidepressant
treatment outcomes in patients with depressive disorders
(Müller et al., 2006; Akhondzadeh et al., 2009). Similarly, NSAIDs
administration decreases severity of emotional alterations in
several animal models of inflammatory diseases, such as cancer
(Norden et al., 2015), Alzheimer’s disease (Llorens-Martin
et al., 2014), and Parkinson’s disease (Zaminelli et al., 2014).
Significant antidepressant effects of the tetracycline antibiotic
minocycline have also been reported in depressed patients
compared to placebo (for review Rosenblat and McIntyre, 2018).
It is also worth mentioning that natural anti-inflammatory
agents, such as ω-3 polyunsaturated fatty acids (PUFAs), have
also shown promising results on mood, particularly as add-on
therapy with conventional antidepressants (for review Layé
et al., 2018). Supporting the link between obesity and depression,
this strategy revealed to be particularly effective in depressed
patients with low-grade basal inflammation (Rapaport et al.,
2016), which is linked to elevated body mass index (BMI).
Interestingly, supplementation with ω-3 PUFAs in obese
subjects also accentuates weight loss induced by low-calorie diet
(Kunesová et al., 2006), weight loss in the context of obesity being
associated – as mentioned earlier – with reduced inflammation
(Lasselin et al., 2014) and improved depressive symptoms
(Emery et al., 2007; Capuron et al., 2011). Current knowledge
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TABLE 1 | Studies investigating antidepressant interventions targeting inflammation, kynurenine or BH4 pathways.
Population/model Treatment Main outcomes
Clinical trials




Improvement of antidepressant treatment




Improvement of antidepressant treatment
Kappelmann et al., 2018
(review and meta-analysis)
Chronic inflammatory conditions Anti-cytokines ↙Depressive symptoms




↙Depression and anxiety scores
Fleming et al., 2015
(databases review)
n = 464 patients
Psoriasis
TNFα blockers ↙Depressive symptoms





Emery et al., 2007 n = 13
Obese women
Weight loss (gastric bypass) ↙Depressive symptoms
↙Inflammatory blood markers (CRP levels)
Pan et al., 2011 Case report (treatment refractory suicidal
ideation)
Sapropterin Mood improvement
Curtius et al., 1983 Case report BH4 Mood improvement
Woggon et al., 1984 Case report BH4 No mood change
Preclinical studies
Norden et al., 2015 Mice
(Cancer-related fatigue)
Ibuprofen ↙Depressive-like behavior and fatigue-like
(FST/wheel running)
↙IL-1b and IL-6 in hippocampus









↙Brain IDO and HAAO mRNA expression











↙Brain KMO mRNA expression
↙Depressive-like behavior
(FST)
Dobos et al., 2012 Mice
(LPS)
1-MT ↙Depressive-like behavior








↙Brain IDO mRNA expression and activity
O’Connor et al., 2009c Mice 1-MT ↙Depressive-like behavior










COX-2, cyclo-oxygenase-2; UCMS, unpredictable chronic mild stress; FST, forced swim test; TST, tail suspension test; IL-1RA, interleukin-1 receptor antagonist;
KMO, kynurenine 3-hydroxylase; 1-MT, 1-methyl tryptophan (IDO inhibitor); LPS, lipopolysaccharide; IDO, indolamine 2,3-dioxygenase; HAAO, hydroxyanthranilic acid
oxygenase.
on the implication of specific inflammatory pathways in driving
neuropsychiatric symptoms also offers the potential for targeted
anti-inflammatory interventions. Thus, monoclonal antibodies
against IL-6, IL-17, and TNF-α display antidepressant effects
in chronically inflamed patients with significant depressive
symptoms, as well as depressed patients with basal low-
grade inflammation (Traki et al., 2014; Gossec et al., 2015;
Griffiths et al., 2017; Jha and Trivedi, 2018; Kappelmann et al.,
2018). Abundant literature also reports antidepressant effects of
anti-TNF-α drugs, such as etanercept or infliximab, in clinical
trials (Kekow et al., 2010; Arisoy et al., 2013; Raison et al.,
2013; Fleming et al., 2015) and murine models of inflammatory
diseases (Haji et al., 2012; Bayramgürler et al., 2013). Of note,
targeting TNF-α in treatment-resistant depressed patients was
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FIGURE 3 | Mechanisms involved in the induction of depressive symptoms in inflammatory conditions (gray arrows) and potential therapeutic implications following
pharmacological or nutritional interventions (blue arrows). Activation of the indoleamine 2,3-dioxygenase (IDO) in inflammatory conditions leads to the production of
kynurenine from tryptophan, at the expense of serotonin production. The synthesis of serotonin and other monoamines is also impaired because of reduced
bioavailability of tetrahydrobiopterin (BH4) that results from the induction of GTP-cyclohydrolase-1 (GCH1) by cytokines. By concomitantly activating the kynurenine
monooxygenase (KMO), inflammation promotes the production of the neurotoxic metabolite quinolinic acid, while synthesis of kynurenic acid, rather neuroprotective,
is reduced. Both inflammation-induced reduction of monoamine production and increase of neuronal damages ultimately contribute to the development of
depressive symptoms. In that context, different therapeutic strategies targeting these mechanisms can be identified. They include: classical antidepressants that aim
to increase monoamine synthesis, but also able of reducing inflammation or kynurenine pathway activation; anti-inflammatory interventions with antibiotics,
ω3-PUFAs, anti-cytokine antibodies or NSAIDs; IDO or KMO inhibitors; antagonists of the NMDA receptors such as ketamine, and BH4 supplementation. PAH,
phenylalanine hydroxylase; TH, tyrosine hydroxylase; TrypOH, tryptophan hydroxylase.
found to improve depressive symptomatology particularly in
those with higher baseline inflammation (Raison et al., 2013),
which tended to be those with higher BMI. In addition, chronic
stress-induced depressive-like behaviors are reduced by TNF-α
antagonism through decreased IDO activation (Fu et al., 2016).
The possibility of acting on brain neurobiological targets of
inflammation, such as the KP, rather than on inflammation itself
has also drawn much attention, particularly since global anti-
inflammatory strategies are often accompanied by important
side effects. Thus, compelling preclinical studies report that
reducing KP activation promotes antidepressant effects (Reus
et al., 2015; Remus and Dantzer, 2016; Jeon and Kim, 2017;
Lovelace et al., 2017; O’Farrell and Harkin, 2017). First promising
on-trial strategies include blockade of KP enzymes, particularly
IDO and KMO, which has been shown to display antidepressant-
like properties whose efficiency varies, however, depending
on what symptom domains were assessed (Toledo-Sherman
et al., 2015; Laumet et al., 2017; Lovelace et al., 2017; Tashiro
et al., 2017). Instead of directly targeting KP enzymes, other
studies have rather investigated the possibility of reducing the
peripheral kynurenine transport across the blood–brain barrier,
as the majority of brain kynurenine comes from the periphery.
This procedure has been indeed shown to prevent production
of QA by activated microglia (Carrillo-Mora et al., 2010),
as well as LPS-induced depressive-like behavior (Remus and
Dantzer, 2016). Alternatively, it may be worthwhile to increase
synthesis/availability of KA, the neuroprotective kynurenine
metabolite (Vécsei et al., 2013). By counteracting the neurotoxic
effect of QA and other NMDA receptor agonists, increasing
KA formation has been shown to reduce neuronal damages
and associated experimentally-induced seizures (Russi et al.,
1992; Silva-Adaya et al., 2011). Similar beneficial effects still
need to be confirmed regarding inflammation-related depressive
symptoms, but these data are already very encouraging. Lastly,
in agreement with the literature that links glutamate with
mood disorders and highlights antidepressant effects of NMDA
receptor antagonists such as ketamine (see for review Haroon
et al., 2017), several interesting studies suggest that targeting
glutamate activity or preventing QA from activating NMDA
receptors also offer additional therapeutic opportunities (Dantzer
and Walker, 2014; Reus et al., 2015). Blocking activation of those
receptors, which was already shown to protect against chronic
stress-induced depressive-like behavior (Li et al., 2011), are
similarly effective regarding LPS-induced behavioral alterations
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(Walker et al., 2013). Moreover, IDO deficient mice are less
sensitive to QA-induced neuronal damages (Mazarei et al., 2013).
Further supporting the role of NMDA receptor activation as
potential therapeutic targets to improve inflammation-related
depressive symptoms, antidepressant treatment was recently
shown to reduce both stress-induced activation of the KP
and changes of NMDA receptor expression (Martín-Hernández
et al., 2018). Similarly, reducing NMDA receptor activation by
enhancing brain KYNA levels has been proposed as a promising
way of counteracting amyloid beta-related neurodegeneration
(Carrillo-Mora et al., 2010).
Even if the potential antidepressant effect of targeting the
BH4 pathway, for example with oral BH4 supplementation, has
been only poorly studied so far and with inconsistent results
(Curtius et al., 1983; Woggon et al., 1984), supplementation
with synthetic BH4 is already used to treat patients suffering
from phenylketonuria (Blau, 2013). Moreover, an interesting
case report shows that administrating a BH4 replacement
protein improves depressive symptoms in a patient suffering
from major depression (Pan et al., 2011). Preclinical data
also highlight the possibility of increasing brain BH4 levels
through its peripheral administration (Ohashi et al., 2016), which
consequently changes serotonin and dopamine metabolism
(Brand et al., 1996), TH protein content (Homma et al.,
2013), dopamine levels and neuronal activities in the brain
(Koshimura et al., 2000). More studies are necessary to test if
such BH4-induced changes in dopamine and norepinephrine
neurotransmission might underlie the expected behavioral
improvement, particularly regarding depression-related
anhedonic symptoms.
Altogether, these findings clearly show that targeting, either
directly or indirectly, inflammation and/or neurobiological
mediators shown to underlie inflammation-driven depressive
symptoms represents promising new therapeutic strategies
(Figure 3). These strategies may not only rely on pharmacological
approaches using currently available drugs prescribed for
their antidepressant properties, but also on the use of still
to discover/validate drugs. Regarding the KP, the potential
beneficial effects of KP enzyme inhibitors are currently
considered in other medical fields, particularly in oncology
(see for review Prendergast et al., 2018). Studies carried out
in the context of inflammation-driven depressive symptoms
should likely benefit therefore from findings reported in other
fields. Beside pharmacological approaches, non-pharmacological
therapeutic strategies, such as nutritional interventions, may
represent a promising alternative associated with reduced risk of
complications and economic cost. This particularly includes diet
supplementation with natural agents such as ω-3 PUFAs, amino
acids or antioxidants, namely compounds known to ultimately
protect against inflammation, oxidative stress and/or other
neurotoxic insults. Importantly, the opportunity to combine
these different therapeutic strategies or rather favor one of them
according to the type of depressive symptoms to treat, should
broaden the spectrum of action of currently used antidepressant
interventions and therefore help improving the management
and/or treatment of depressive symptoms associated with
inflammation.
CONCLUSION
Given the steadily rising prevalence of depression and
inflammation-based chronic diseases, their combined negative
impact on the etiology of other severe diseases, and the
elevated resistance to conventional antidepressants, a better
understanding of the pathophysiological mechanisms of
inflammation-driven depressive symptoms is urgently required
for the identification of new and efficacious therapeutic strategies.
Altogether, findings discussed in the present review show
that strategies directed to inflammatory processes might be
particularly promising, because of their pivotal role in the
pathophysiology of depression and their substantial impact
on the metabolism of monoamines involved in the regulation
of mood. Despite the important advances made over the last
decade, several issues are still at stake, from the identification
of the best candidates to be targeted within the inflammatory
pathways to the determination of the most suitable protocol
of treatment (i.e., anti-inflammatory strategies as treatment
or co-treatment with conventional antidepressants). Resolving
these issues, which clearly depend on the patient’s individual
characteristics, constitutes a crucial challenge for the future, as
it should allow personalizing antidepressant prescription, and in
turn contributing to the development of a precision medicine in
psychiatry.
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